Cilta-cel’s mechanism of action allows it to penetrate challenging areas of multiple myeloma, providing deep and durable ...

Panelists highlight advances in myeloma treatment, focusing on innovative T cell therapies like CAR T and T-cell engagers, ...

The intervention involves the investigational drug ABBV-453, a BCL-2 inhibitor, administered orally. It is tested alone or in combination with daratumumab, dexamethasone, and pomalidomide, aiming to ...

An expert discusses how treatment guidelines and institutional pathways are evolving to integrate CAR T-cell therapies and bispecific antibodies for relapsed/refractory multiple myeloma (R/R MM), ...

Janssen’s drug JNJ-68284528 is currently being evaluated for the treatment of CAR T-Cell Therapy for Multiple Myeloma. The ...

Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...

Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity ...

An expert discusses the growing importance of real-world evidence in informing payer decisions and value-based care strategies for bispecific therapies in relapsed/refractory multiple myeloma (R/R MM) ...

Your risk for multiple myeloma (MM) increases as you age. In fact, 35% of the patients are diagnosed at age 75 or older, including 10% who are 85 or older. The average age for this type of blood ...

If you've been diagnosed with multiple myeloma, your doctor may toss around medical terms that sound like a foreign language to you. Get the definitions for important tests, symptoms, and treatments.

Multiple myeloma is a cancer of the bone marrow, with a life expectancy of less than 5 years post-diagnosis. Proteasome inhibitors, the therapeutic backbone of current treatments, are very ...